The ORIENT-31 trial evaluated the combination of an anti-PD-1 agent (sintilimab), an anti-VEGF agent (IBI305), and chemotherapy in EGFR-mutant NSCLC after EGFR TKI failure [107]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.